

PHARMACEUTICAL 2023

ESSA Pharma Inc. Rank 10 of 446







RealRate

PHARMACEUTICAL 2023

ESSA Pharma Inc. Rank 10 of 446

The relative strengths and weaknesses of ESSA Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ESSA Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of ESSA Pharma Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 294%, being 250% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	169,059
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,310
Liabilities, Non-Current	76
Other Assets	446
Other Compr. Net Income	-59
Other Expenses	-98
Other Liabilities	0
Other Net Income	22
Other Revenues	1,737
Property and Equipment	0
Research and Development	24,415
Selling, General and Administrative Expense	12,545

Output Variable	Value in 1000 USD
Assets	169,505
Liabilities	2,387
Expenses	36,862
Revenues	1,737
Stockholders Equity	167,118
Net Income	-35,103
Comprehensive Net Income	-35,133
Economic Capital Ratio	294%

